Martinsried-Munich, Germany (July 22, 2025) – Coriolis Pharma, a globally operating Contract Research and Development Organization (CRDO) and a leader in formulation research and development for biopharmaceuticals, today announced its intention to invest $10 million in establishing a state-of-the-art research laboratory and creating 50 jobs at Spark LS, an innovative life science campus in Morrisville, North Carolina.
The new laboratory will encompass approximately 13,000 square feet and is scheduled to commence operations in the first quarter of 2026. As a strategic anchor for Coriolis Pharma’s North American expansion, the facility will initially deliver core services such as particle identification, followed by formulation development and lyophilization. These offerings will be seamlessly integrated with the company’s global scientific and operational network, ensuring continuity and excellence through close collaboration with its headquarters in Germany. The site is designed to support future innovation, including the adoption of advanced digital and in-silico technologies, reinforcing Coriolis Pharma’s vision to accelerate and de-risk biopharmaceutical development.
KSM Location Advisors is pleased to have negotiated approximately $273,236 in incentives for Coriolis Pharma.